Elderly populations are boosting the market for acute pain medications, as chronic disease and vulnerability to accidents demand ever-increasing levels of care, according to a new report. The report from GlobalData states that while cheap and effective generic drugs set a high standard for upcoming products, research is still going strong in the hope of discovering a revolutionary new blockbuster painkiller. Elderly patients are more prone to injuries such as bone fractures and chronic diseases such as osteoarthritis, and undergo higher numbers of surgerical procedures such as joint replacements. Acute pain is currently treated using several drug classes effective in decreasing pain intensity by a significant level, namely opioids, NSAIDs, COX2 inhibitors, weak COX1 and COX2 inhibitors, and local anesthetics. However, market growth is expected due to the upcoming launch of drugs in the late stages of clinical development, such as Dyloject (diclofenac sodium fastpush intravenous bolus injection) in the US, Ketotransdel (ketoprofen 10% Cream) and MRX-7EAT (etodolac + lidocaine topical patch), which all utilise novel drug delivery technology.